Table 3.
SV40 seropositivity related to gender among Colombian and Nicaraguan subjectsa
| Country | Group | Group criteria | No. SV40 antibody positive/No. tested (%)b | ||
|---|---|---|---|---|---|
| Female | Male | Total | |||
| Colombia | A+B | Cancers + controls | 19/140 (13.6) | 0 | 19/140 (13.6) |
| C | General population | 34/140 (24.3) | 39/168 (23.4) | 73/308 (23.2) | |
| D | Sex workers | 22/57 (38.6) | 0 | 22/57 (38.6) | |
| Total (Groups A-D): | 75/338 (22.2) | 39/167 (23.4) | 114/505 (22.6) | ||
| Nicaragua | E | Endoscopy patients | 12/111 (10.8) | 7/38 (18.4) | 19/149 (12.8) |
a
Samples that lacked donor gender information were not included.
b
Statistical significance: Group C (female vs. male), p = 0.7270; Group E (female vs. male), p = 0.1099; Group C (female) vs. Group D (female), p = 0.033; Group C (female) vs. Group E (female), p = 0.0089; Group C -(vbc) (female) vs. Groups A+B, p = 0.0757. (vbc) = Birth cohort that contains potential vaccinees (birth dates 1949–1960).